Monash IVF Group (MVF) H1 2026 earnings summary

Executive summary

• Underlying NPAT for 1H26 was AUD 10.4 million, down 34% year-over-year but at the upper end of guidance, with revenue at AUD 137.9 million, down 1.8% due to lower Australian IVF volumes and market share.

• Operational stability returned after disruptions in late FY25 and early FY26, with a leadership transition underway and new CEO and CFO recruitment in progress.

• Clinical pregnancy rates improved year-on-year, reaching 40.7% for women under 43, with strong performance in women under 35.

• Major infrastructure cycle is concluding, with new Brisbane Clinic and Day Hospital opening in Q4 FY26, positioning for improved capital efficiency and organic margin growth.

• Strategic focus remains on restoring core performance, margin growth, and leadership alignment.

Financial highlights

• Underlying EBITDA was AUD 30.2 million with a margin of 22%, down 15.3% year-over-year, impacted by industry softness, non-recurring legal/compliance costs, and wage inflation.

• Reported NPAT was AUD 7.5 million, down 56.4% year-over-year.

• Free cash flow improved to AUD 5 million from negative AUD 6.2 million in the prior period.

• Interim fully franked dividend of AUD 0.012 per share declared.

• Net debt increased to AUD 94.9 million, with a leverage ratio of 2.0x.

Outlook and guidance

• FY26 underlying NPAT guidance reaffirmed at AUD 20 million, with full-year capital expenditure expected at AUD 16–17 million as major infrastructure projects complete in Q4 FY26.

• Dividend payout policy remains at 60–70% of full-year underlying earnings.

• Net leverage ratio expected to remain at 2.0x, well below covenant limits.

• Anticipated patient price increases and operational efficiency expected to drive earnings and margin growth in FY27.

• Industry growth expected to return from FY27, with early signs of patient activity recovery and increased inquiries.